CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Lilly and Resilience invest $750M in diabetes and obesity drug device supply

PartnershipKwikPenPositive
AI Analysis

Summary

Eli Lilly and Resilience announced a $750M investment to expand U.S. manufacturing capacity for the KwikPen device used to deliver Lilly's injectable diabetes and obesity medicines.

Importance:5/10
Sentiment:
0.60
manufacturingdevicesupply chaindiabetesobesityinjectable
Related Companies

Read the original article

Published by BioSpace on July 31, 2026 4:28 PM

Read Original